Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kalaris Therapeutics's ebitda for the twelve months ending Dec 31, 2023 was -$199.50M. For fiscal 2023 it was -$199.50M. The highest annual figure on record is -$26.68M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$199.50M | – |
| FY2022 | Dec 31, 2022 | -$170.48M | – |
| FY2021 | Dec 31, 2021 | -$169.63M | – |
| FY2020 | Dec 31, 2020 | -$71.24M | – |
| FY2019 | Dec 31, 2019 | -$26.68M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$62.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.82M | – |
See a number that looks wrong?